{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:28:02Z","timestamp":1773743282459,"version":"3.50.1"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"sociedade brasileira de reumatologia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriatic arthritis (PsA) is a chronic and systemic immune disease characterized by inflammation of peripheral and\/or axial joints and entheses in patients with psoriasis (PsO). Extra-articular and extracutaneous manifestations and numerous comorbidities can also be present. These recommendations replace the previous version published in May 2013. A systematic review of the literature retrieved 191 articles that were used to formulate 12 recommendations in response to 12 clinical questions, divided into 4 sections: diagnosis, non-pharmacological treatment, conventional drug therapy and biologic therapy. These guidelines provide evidence-based information on the clinical management for PsA patients. For each recommendation, the level of evidence (highest available), degree of strength (Oxford) and degree of expert agreement (interrater reliability) are reported.<\/jats:p>","DOI":"10.1186\/s42358-021-00219-y","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T10:02:44Z","timestamp":1637748164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis"],"prefix":"10.1186","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7515-2365","authenticated-orcid":false,"given":"Sueli","family":"Carneiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope Esther","family":"Palominos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f4nia Maria Alvarenga","family":"Anti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Luppino","family":"Assad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela Silva Guimar\u00e3es","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Chiereghin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Marun","family":"Lyrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio Carlos","family":"Ximenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Gon\u00e7alves","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lio Roberto","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles Lubianca","family":"Kohem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia Diniz Lopes","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia Goldenstein","family":"Schainberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"de Souza Meirelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo Gomes","family":"Resende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenise Brandao","family":"Pieruccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro Waldemar","family":"Keiserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Alexandre","family":"Yazbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percival Degrava","family":"Sampaio-Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"da Cruz Lage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubens","family":"Bonfiglioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thauana Lu\u00edza","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valder\u00edlio Feij\u00f3","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Washington Alves","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanderley Marques","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"dos Santos Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"de Medeiros Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano Barbosa","family":"Campanholo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"1","key":"219_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","volume":"48","author":"L Scotti","year":"2018","unstructured":"Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(1):28\u201334. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.003.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"219_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"219_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3899\/jrheum.140474","volume":"42","author":"R Ranza","year":"2015","unstructured":"Ranza R, Carneiro S, Qureshi AA, et al. Prevalence of psoriatic arthritis in a large cohort of Brazilian patients with psoriasis. J Rheumatol. 2015;42(5):829\u201334. https:\/\/doi.org\/10.3899\/jrheum.140474.","journal-title":"J Rheumatol"},{"issue":"12","key":"219_CR4","first-page":"2638","volume":"30","author":"R Scarpa","year":"2003","unstructured":"Scarpa R, Cosentini E, Manguso F, et al. Clinical and genetic aspects of psoriatic arthritis \u201csine psoriasis.\u201d J Rheumatol. 2003;30(12):2638\u201340.","journal-title":"J Rheumatol"},{"issue":"4","key":"219_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.rdc.2015.07.007","volume":"41","author":"RP Poggenborg","year":"2015","unstructured":"Poggenborg RP, \u00d8stergaard M, Terslev L. Imaging in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):593\u2013613. https:\/\/doi.org\/10.1016\/j.rdc.2015.07.007.","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"219_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208337.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 11","key":"219_CR7","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis: tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S64-85. https:\/\/doi.org\/10.1002\/acr.20577.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"219_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42358-020-0116-2","volume":"60","author":"GG Resende","year":"2020","unstructured":"Resende GG, Meirelles ES, Marques CDL, Chiereghin A, Lyrio AM, Ximenes AC, Saad CG, Gon\u00e7alves CR, Kohem CL, Schainberg CG, Campanholo CB, Bueno Filho JSS, Pieruccetti LB, Keiserman MW, Yazbek MA, Palominos PE, Goncalves RSG, Lage RDC, Assad RL, Bonfiglioli R, Anti SMA, Carneiro S, Oliveira TL, Azevedo VF, Bianchi WA, Bernardo WM, Pinheiro MM, Sampaio-Barros PD. The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis\u20142019. Adv Rheumatol. 2020;60(1):19. https:\/\/doi.org\/10.1186\/s42358-020-0116-2.","journal-title":"Adv Rheumatol"},{"issue":"5","key":"219_CR9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371. https:\/\/doi.org\/10.1002\/art.39573.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"219_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332. https:\/\/doi.org\/10.1002\/art.40726.","journal-title":"Arthritis Rheumatol"},{"key":"219_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1590\/S0482-50042013000300002","volume":"53","author":"S Carneiro","year":"2013","unstructured":"Carneiro S, Azevedo VF, Bonfiglioli R, et al. Recommendations for the management and treatment of psoriatic arthritis. Rev Bras Reumatol. 2013;53:227\u201341.","journal-title":"Rev Bras Reumatol"},{"issue":"8","key":"219_CR12","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"issue":"7650","key":"219_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"7","key":"219_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719\u201325. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.03.013.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"219_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Sch\u00fcnemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol. 2013;66(7):726\u201335. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.02.003.","journal-title":"J Clin Epidemiol"},{"key":"219_CR16","unstructured":"Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, Moschetti I, Phillips B, Thornton H; OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. 2011. www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence"},{"issue":"4","key":"219_CR17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008\u201315.","journal-title":"J Adv Nurs"},{"key":"219_CR18","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.","edition":"2"},{"key":"219_CR19","doi-asserted-by":"publisher","unstructured":"Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists [published correction appears in Biol Rev Camb Philos Soc. 2009 Aug;84(3):515]. Biol Rev Camb Philos Soc. 2007;82(4):591\u2013605. https:\/\/doi.org\/10.1111\/j.1469-185X.2007.00027","DOI":"10.1111\/j.1469-185X.2007.00027"},{"issue":"3","key":"219_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/bjd.14604","volume":"175","author":"LC Coates","year":"2016","unstructured":"Coates LC, Savage L, Waxman R, Moverley AR, Worthington S, Helliwell PS. Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study. Br J Dermatol. 2016;175(3):542\u20138. https:\/\/doi.org\/10.1111\/bjd.14604.","journal-title":"Br J Dermatol"},{"key":"219_CR21","doi-asserted-by":"publisher","unstructured":"Coates LC, Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study) [published correction appears in Br J Dermatol. 2013 Jun;168(6):1376. Burden-The, E [corrected to Burden-Teh, Esther]]. Br J Dermatol. 2013;168(4):802\u2013807. https:\/\/doi.org\/10.1111\/bjd.12190","DOI":"10.1111\/bjd.12190"},{"issue":"5","key":"219_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.140857","volume":"42","author":"BD Tom","year":"2015","unstructured":"Tom BD, Chandran V, Farewell VT, Rosen CF, Gladman DD. Validation of the Toronto psoriatic arthritis screen version 2 (ToPAS 2). J Rheumatol. 2015;42(5):841\u20136. https:\/\/doi.org\/10.3899\/jrheum.140857.","journal-title":"J Rheumatol"},{"issue":"3","key":"219_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/bjd.14929","volume":"176","author":"S Mishra","year":"2017","unstructured":"Mishra S, Kancharla H, Dogra S, Sharma A. Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study). Br J Dermatol. 2017;176(3):765\u201370. https:\/\/doi.org\/10.1111\/bjd.14929.","journal-title":"Br J Dermatol"},{"issue":"11","key":"219_CR24","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/jdv.14861","volume":"32","author":"E Audureau","year":"2018","unstructured":"Audureau E, Roux F, Lons Danic D, et al. Psoriatic arthritis screening by the dermatologist: development and first validation of the \u201cPURE-4 scale.\u201d J Eur Acad Dermatol Venereol. 2018;32(11):1950\u20133. https:\/\/doi.org\/10.1111\/jdv.14861.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"219_CR25","first-page":"127","volume":"36","author":"F Salaffi","year":"2018","unstructured":"Salaffi F, Di Carlo M, Luchetti MM, et al. A validation study of the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. Clin Exp Rheumatol. 2018;36(1):127\u201335.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"219_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2007.04.001","volume":"57","author":"ME Husni","year":"2007","unstructured":"Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57(4):581\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2007.04.001.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"219_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5021\/ad.2015.27.3.265","volume":"27","author":"HS You","year":"2015","unstructured":"You HS, Kim GW, Cho HH, et al. Screening for psoriatic arthritis in Korean psoriasis patients using the psoriatic arthritis screening evaluation questionnaire. Ann Dermatol. 2015;27(3):265\u20138. https:\/\/doi.org\/10.5021\/ad.2015.27.3.265.","journal-title":"Ann Dermatol"},{"issue":"4","key":"219_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/rheumatology\/kew410","volume":"56","author":"MC Karreman","year":"2017","unstructured":"Karreman MC, Weel AEAM, van der Ven M, et al. Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. Rheumatology (Oxford). 2017;56(4):597\u2013602. https:\/\/doi.org\/10.1093\/rheumatology\/kew410.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"219_CR29","first-page":"469","volume":"27","author":"GH Ibrahim","year":"2009","unstructured":"Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"219_CR30","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/rheumatology\/kes187","volume":"51","author":"I Tinazzi","year":"2012","unstructured":"Tinazzi I, Adami S, Zanolin EM, et al. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford). 2012;51(11):2058\u201363. https:\/\/doi.org\/10.1093\/rheumatology\/kes187.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"219_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/rheumatology\/key314.PMID:30380111;PMCID:PMC6434376","volume":"58","author":"N Iragorri","year":"2019","unstructured":"Iragorri N, Hazlewood G, Manns B, Danthurebandara V, Spackman E. Psoriatic arthritis screening: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58(4):692\u2013707. https:\/\/doi.org\/10.1093\/rheumatology\/key314.PMID:30380111;PMCID:PMC6434376.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"219_CR32","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/jdv.14971","volume":"32","author":"LC Coates","year":"2018","unstructured":"Coates LC, Savage LJ, Chinoy H, et al. Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. J Eur Acad Dermatol Venereol. 2018;32(9):1530\u20134. https:\/\/doi.org\/10.1111\/jdv.14971.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"219_CR33","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s10067-020-05509-2","volume":"40","author":"RSG Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves RSG, Pereira GA, de Andrade LE, Martins THF, Junior JOA, Carvalho JB, Mariz HA, Dantas AT, Duarte ALBP. Validation of the Toronto Psoriatic Arthritis Screen II (ToPAS II) questionnaire in a Brazilian population. Clin Rheumatol. 2021;40(5):1889\u201392. https:\/\/doi.org\/10.1007\/s10067-020-05509-2.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"219_CR34","doi-asserted-by":"publisher","first-page":"e0205486","DOI":"10.1371\/journal.pone.0205486","volume":"13","author":"CZ Costa","year":"2018","unstructured":"Costa CZ, Goldenstein-Schainberg C, Carneiro S, Rodrigues JJ, Romiti R, Barros TBM, et al. Semantic and psychometric validation of the Brazilian Portuguese version (PASE-P) of the psoriatic arthritis screening and evaluation questionnaire. PLoS ONE. 2018;13(10):e0205486. https:\/\/doi.org\/10.1371\/journal.pone.0205486.","journal-title":"PLoS ONE"},{"issue":"3","key":"219_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00403-019-02013-9","volume":"312","author":"NG Mazzotti","year":"2020","unstructured":"Mazzotti NG, Palominos PE, Bredemeier M, Kohem CL, Cestari TF. Cross-cultural validation and psychometric properties of the Brazilian Portuguese version of the Psoriasis Epidemiology Screening Tool (PEST-bp). Arch Dermatol Res. 2020;312(3):197\u2013206. https:\/\/doi.org\/10.1007\/s00403-019-02013-9.","journal-title":"Arch Dermatol Res"},{"issue":"238","key":"219_CR36","first-page":"127","volume":"62","author":"DD Gladman","year":"1987","unstructured":"Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)\u2014an analysis of 220 patients. Q J Med. 1987;62(238):127\u201341.","journal-title":"Q J Med"},{"issue":"9","key":"219_CR37","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/rheumatology\/33.9.834","volume":"33","author":"SM Jones","year":"1994","unstructured":"Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33(9):834\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/33.9.834.","journal-title":"Br J Rheumatol"},{"issue":"12","key":"219_CR38","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1468-3083.2011.03985.x","volume":"25","author":"Q Yang","year":"2011","unstructured":"Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25(12):1409\u201314. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.03985.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"219_CR39","doi-asserted-by":"publisher","unstructured":"Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study [published correction appears in Arthritis Rheum. 2010 Apr;62(4):574]. Arthritis Rheumil. 2009;61(2):233\u2013239. doi:https:\/\/doi.org\/10.1002\/art.24172","DOI":"10.1002\/art.24172"},{"issue":"7","key":"219_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1365-4362.1992.tb02696.x","volume":"31","author":"MD Zanolli","year":"1992","unstructured":"Zanolli MD, Wikle JS. Joint complaints in psoriasis patients. Int J Dermatol. 1992;31(7):488\u201391. https:\/\/doi.org\/10.1111\/j.1365-4362.1992.tb02696.x.","journal-title":"Int J Dermatol"},{"issue":"3","key":"219_CR41","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/kes324","volume":"52","author":"A Ogdie","year":"2013","unstructured":"Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford). 2013;52(3):568\u201375. https:\/\/doi.org\/10.1093\/rheumatology\/kes324.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"219_CR42","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3899\/jrheum.111298","volume":"39","author":"TJ Love","year":"2012","unstructured":"Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B. Psoriatic arthritis and onycholysis\u2014results from the cross-sectional Reykjavik psoriatic arthritis study. J Rheumatol. 2012;39(7):1441\u20134. https:\/\/doi.org\/10.3899\/jrheum.111298.","journal-title":"J Rheumatol"},{"issue":"1","key":"219_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/rheumatology\/keq262","volume":"50","author":"DD Gladman","year":"2011","unstructured":"Gladman DD, Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford). 2011;50(1):25\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/keq262.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"219_CR44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/archdermatol.2010.141","volume":"146","author":"R Soltani-Arabshahi","year":"2010","unstructured":"Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. 2010;146(7):721\u20136. https:\/\/doi.org\/10.1001\/archdermatol.2010.141.","journal-title":"Arch Dermatol"},{"issue":"5","key":"219_CR45","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","volume":"160","author":"K Reich","year":"2009","unstructured":"Reich K, Kr\u00fcger K, M\u00f6ssner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.09023.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"219_CR46","first-page":"162","volume":"11","author":"F Jamshidi","year":"2008","unstructured":"Jamshidi F, Bouzari N, Seirafi H, Farnaghi F, Firooz A. The prevalence of psoriatic arthritis in psoriatic patients in Tehran. Iran Arch Iran Med. 2008;11(2):162\u20135.","journal-title":"Iran Arch Iran Med"},{"issue":"8","key":"219_CR47","first-page":"1499","volume":"22","author":"C Salvarani","year":"1995","unstructured":"Salvarani C, Lo Scocco G, Macchioni P, et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol. 1995;22(8):1499\u2013503.","journal-title":"J Rheumatol"},{"issue":"2","key":"219_CR48","first-page":"315","volume":"12","author":"RS Stern","year":"1985","unstructured":"Stern RS. The epidemiology of joint complaints in patients with psoriasis. J Rheumatol. 1985;12(2):315\u201320.","journal-title":"J Rheumatol"},{"issue":"2","key":"219_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00296-008-0686-5","volume":"29","author":"M Soy","year":"2008","unstructured":"Soy M, Karaca N, Umit EU, Bes C, Piskin S. Joint and nail involvement in Turkish patients with psoriatic arthritis. Rheumatol Int. 2008;29(2):223\u20135. https:\/\/doi.org\/10.1007\/s00296-008-0686-5.","journal-title":"Rheumatol Int"},{"issue":"8","key":"219_CR50","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/acr.20496","volume":"63","author":"L Eder","year":"2011","unstructured":"Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(8):1091\u20137. https:\/\/doi.org\/10.1002\/acr.20496.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"219_CR51","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1365-4632.2009.04452.x","volume":"49","author":"H Maejima","year":"2010","unstructured":"Maejima H, Taniguchi T, Watarai A, Katsuoka K. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int J Dermatol. 2010;49(8):901\u20136. https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04452.x.","journal-title":"Int J Dermatol"},{"issue":"4","key":"219_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/03009741003604559","volume":"39","author":"TJ Love","year":"2010","unstructured":"Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B. Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. Scand J Rheumatol. 2010;39(4):299\u2013302. https:\/\/doi.org\/10.3109\/03009741003604559.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"219_CR53","first-page":"757","volume":"29","author":"J Thumboo","year":"2002","unstructured":"Thumboo J, Uramoto K, Shbeeb MI, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol. 2002;29(4):757\u201362.","journal-title":"J Rheumatol"},{"issue":"7","key":"219_CR54","first-page":"1315","volume":"33","author":"R Scarpa","year":"2006","unstructured":"Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol. 2006;33(7):1315\u20139.","journal-title":"J Rheumatol"},{"key":"219_CR55","unstructured":"Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999;26(8):1752\u20131756"},{"issue":"3","key":"219_CR56","first-page":"279","volume":"12","author":"M Moghaddassi","year":"2009","unstructured":"Moghaddassi M, Shahram F, Chams-Davatchi C, Najafizadeh SR, Davatchi F. Different aspects of psoriasis: analysis of 150 Iranian patients. Arch Iran Med. 2009;12(3):279\u201383.","journal-title":"Arch Iran Med"},{"issue":"1","key":"219_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10067-003-0817-z","volume":"23","author":"R Scarpa","year":"2004","unstructured":"Scarpa R, Manguso F, Oriente A, Peluso R, Atteno M, Oriente P. Is the involvement of the distal interphalangeal joint in psoriatic patients related to nail psoriasis? Clin Rheumatol. 2004;23(1):27\u201330. https:\/\/doi.org\/10.1007\/s10067-003-0817-z.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"219_CR58","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/acr.20627","volume":"63","author":"JA Husted","year":"2011","unstructured":"Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(12):1729\u201335. https:\/\/doi.org\/10.1002\/acr.20627.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"219_CR59","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/ker349","volume":"51","author":"VM Bhole","year":"2012","unstructured":"Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51(3):552\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/ker349.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"219_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/acr.23094","volume":"69","author":"K Jafri","year":"2017","unstructured":"Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2017;69(1):51\u20137. https:\/\/doi.org\/10.1002\/acr.23094.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"219_CR61","doi-asserted-by":"publisher","unstructured":"Kaine J, Song X, Kim G, Hur P, Palmer JB. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. Administrative claims data.\u00a0J Manag Care Spec Pharm. 2019;25(1):122\u2013132. https:\/\/doi.org\/10.18553\/jmcp.2018.17421","DOI":"10.18553\/jmcp.2018.17421"},{"issue":"1","key":"219_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/acr.21711","volume":"65","author":"MN Di Minno","year":"2013","unstructured":"Di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken). 2013;65(1):141\u20137. https:\/\/doi.org\/10.1002\/acr.21711.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"219_CR63","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MN Di Minno","year":"2014","unstructured":"Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann Rheum Dis. 2014;73(6):1157\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202812.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"219_CR64","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3899\/jrheum.140021","volume":"41","author":"M Haroon","year":"2014","unstructured":"Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014;41(7):1357\u201365. https:\/\/doi.org\/10.3899\/jrheum.140021.","journal-title":"J Rheumatol"},{"key":"219_CR65","doi-asserted-by":"publisher","unstructured":"\u00d6zkan SG, Yaz\u0131s\u0131z H, Behl\u00fcl A, G\u00f6kbelen YA, Borlu F, Yaz\u0131s\u0131z V. Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis [published correction appears in Eur J Rheumatol. 2017 Dec;4(4):307].\u00a0Eur J Rheumatol. 2017;4(1):40\u201345. https:\/\/doi.org\/10.5152\/eurjrheum.2017.16052","DOI":"10.5152\/eurjrheum.2017.16052"},{"issue":"2","key":"219_CR66","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3899\/jrheum.141359","volume":"43","author":"N Haque","year":"2016","unstructured":"Haque N, Lories RJ, de Vlam K. Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol. 2016;43(2):376\u201382. https:\/\/doi.org\/10.3899\/jrheum.141359.","journal-title":"J Rheumatol"},{"issue":"4","key":"219_CR67","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/met.2009.0124","volume":"8","author":"SK Raychaudhuri","year":"2010","unstructured":"Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8(4):331\u20134. https:\/\/doi.org\/10.1089\/met.2009.0124.","journal-title":"Metab Syndr Relat Disord"},{"issue":"12","key":"219_CR68","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s10067-016-3362-2","volume":"35","author":"N Ahmed","year":"2016","unstructured":"Ahmed N, Prior JA, Chen Y, Hayward R, Mallen CD, Hider SL. Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clin Rheumatol. 2016;35(12):3069\u201373. https:\/\/doi.org\/10.1007\/s10067-016-3362-2.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"219_CR69","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10067-011-1692-7","volume":"30","author":"M Khraishi","year":"2011","unstructured":"Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS. Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol. 2011;30(7):877\u201385. https:\/\/doi.org\/10.1007\/s10067-011-1692-7.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"219_CR70","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.3899\/jrheum.160542","volume":"43","author":"L Costa","year":"2016","unstructured":"Costa L, Caso F, Del Puente A, Di Minno MN, Peluso R, Scarpa R. Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying antirheumatic drug and tumor necrosis factor inhibitor therapy: an observational study. J Rheumatol. 2016;43(12):2149\u201354. https:\/\/doi.org\/10.3899\/jrheum.160542.","journal-title":"J Rheumatol"},{"issue":"11","key":"219_CR71","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167\u201372.","journal-title":"J Rheumatol"},{"issue":"3","key":"219_CR72","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/art.40389","volume":"70","author":"A Szentpetery","year":"2018","unstructured":"Szentpetery A, Healy GM, Brady D, et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol. 2018;70(3):396\u2013407. https:\/\/doi.org\/10.1002\/art.40389.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"219_CR73","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","volume":"21","author":"L Li","year":"2015","unstructured":"Li L, Hagberg KW, Peng M, Shah K, Paris M, Jick S. Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis. J Clin Rheumatol. 2015;21(8):405\u201310. https:\/\/doi.org\/10.1097\/RHU.0000000000000306.","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"219_CR74","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2016.11.046","volume":"76","author":"P Kathuria","year":"2017","unstructured":"Kathuria P, Gordon KB, Silverberg JI. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol. 2017;76(6):1045\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.046.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"219_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/ard.59.1.67","volume":"59","author":"ES Paiva","year":"2000","unstructured":"Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000;59(1):67\u201370. https:\/\/doi.org\/10.1136\/ard.59.1.67.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"219_CR76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","volume":"19","author":"K Bengtsson","year":"2017","unstructured":"Bengtsson K, Forsblad-d\u2019Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017;19(1):102. https:\/\/doi.org\/10.1186\/s13075-017-1315-z.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"219_CR77","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s10067-016-3374-y","volume":"35","author":"A Zohar","year":"2016","unstructured":"Zohar A, Cohen AD, Bitterman H, et al. Gastrointestinal comorbidities in patients with psoriatic arthritis. Clin Rheumatol. 2016;35(11):2679\u201384. https:\/\/doi.org\/10.1007\/s10067-016-3374-y.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"219_CR78","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/acr.23614","volume":"71","author":"RS Thomsen","year":"2019","unstructured":"Thomsen RS, Nilsen TIL, Haugeberg G, Bye A, Kavanaugh A, Hoff M. Impact of High-intensity interval training on disease activity and disease in patients with psoriatic arthritis: a randomized controlled trial. Arthritis Care Res (Hoboken). 2019;71(4):530\u20137. https:\/\/doi.org\/10.1002\/acr.23614.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"219_CR79","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10067-017-3917-x","volume":"37","author":"D Roger-Silva","year":"2018","unstructured":"Roger-Silva D, Natour J, Moreira E, Jennings F. A resistance exercise program improves functional capacity of patients with psoriatic arthritis: a randomized controlled trial. Clin Rheumatol. 2018;37(2):389\u201395. https:\/\/doi.org\/10.1007\/s10067-017-3917-x.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"219_CR80","doi-asserted-by":"publisher","first-page":"e000729","DOI":"10.1136\/rmdopen-2018-000729","volume":"4","author":"RS Thomsen","year":"2018","unstructured":"Thomsen RS, Nilsen TIL, Haugeberg G, Bye A, Kavanaugh A, Hoff M. Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial. RMD Open. 2018;4(2):e000729. https:\/\/doi.org\/10.1136\/rmdopen-2018-000729.","journal-title":"RMD Open"},{"issue":"6","key":"219_CR81","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1517\/14712598.2014.900541","volume":"14","author":"N Al-Mutairi","year":"2014","unstructured":"Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Exp Opin Biol Ther. 2014;14(6):749\u201356. https:\/\/doi.org\/10.1517\/14712598.2014.900541.","journal-title":"Exp Opin Biol Ther"},{"issue":"7","key":"219_CR82","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/acr.20146","volume":"62","author":"A Baillet","year":"2010","unstructured":"Baillet A, Zeboulon N, Gossec L, et al. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken). 2010;62(7):984\u201392. https:\/\/doi.org\/10.1002\/acr.20146.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"219_CR83","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/rheumatology\/keq102","volume":"49","author":"L Eder","year":"2010","unstructured":"Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford). 2010;49(7):1367\u201373. https:\/\/doi.org\/10.1093\/rheumatology\/keq102.","journal-title":"Rheumatology (Oxford)"},{"key":"219_CR84","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/PTT.S52893","volume":"5","author":"GH Kingsley","year":"2015","unstructured":"Kingsley GH, Scott DL. Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis\u2014a systematic review. Psoriasis (Auckl). 2015;5:71\u201381. https:\/\/doi.org\/10.2147\/PTT.S52893.","journal-title":"Psoriasis (Auckl)"},{"issue":"7","key":"219_CR85","first-page":"1422","volume":"33","author":"ER Soriano","year":"2006","unstructured":"Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33(7):1422\u201330.","journal-title":"J Rheumatol"},{"issue":"3","key":"219_CR86","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF01451052","volume":"17","author":"W Grassi","year":"1998","unstructured":"Grassi W, De Angelis R, Cervini C. Corticosteroid prescribing in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol. 1998;17(3):223\u20136. https:\/\/doi.org\/10.1007\/BF01451052.","journal-title":"Clin Rheumatol"},{"issue":"1 Suppl 22","key":"219_CR87","first-page":"S17","volume":"19","author":"P Sarzi-Puttini","year":"2001","unstructured":"Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol. 2001;19(1 Suppl 22):S17\u201320.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"219_CR88","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.semarthrit.2007.03.004","volume":"37","author":"AJ Kivitz","year":"2007","unstructured":"Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum. 2007;37(3):164\u201373. https:\/\/doi.org\/10.1016\/j.semarthrit.2007.03.004.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"219_CR89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1185\/03007997609109283","volume":"4","author":"A Lassus","year":"1976","unstructured":"Lassus A. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter\u2019s disease. Curr Med Res Opin. 1976;4(1):65\u20139. https:\/\/doi.org\/10.1185\/03007997609109283.","journal-title":"Curr Med Res Opin"},{"issue":"8A","key":"219_CR90","first-page":"1440","volume":"30","author":"G Lonauer","year":"1980","unstructured":"Lonauer G, Wirth W. Kontrollierte Doppelblindstudie zur Uberpr\u00fcfung der Wirksamkeit und Vertr\u00e4glichkeit von Acemetacin und Indometacin bei der Behandlung der Arthritis psoriatica [Controlled double blind study on the effectiveness and adverse effects of acemetacin and indomethacin in the treatment of psoriatic arthritis]. Arzneimittelforschung. 1980;30(8A):1440\u20134.","journal-title":"Arzneimittelforschung"},{"issue":"1\u20132","key":"219_CR91","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF01965150","volume":"12","author":"PA Leatham","year":"1982","unstructured":"Leatham PA, Bird HA, Wright V, Fowler PD. The run-in period in trial design: a comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy. Agents Actions. 1982;12(1\u20132):221\u20134. https:\/\/doi.org\/10.1007\/BF01965150.","journal-title":"Agents Actions"},{"issue":"4","key":"219_CR92","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/art.20985","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005;52(4):1205\u201315. https:\/\/doi.org\/10.1002\/art.20985.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"219_CR93","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landew\u00e9 R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756\u201365. https:\/\/doi.org\/10.1002\/art.21054.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"219_CR94","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207897.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"219_CR95","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","volume":"71","author":"F Kroon","year":"2012","unstructured":"Kroon F, Landew\u00e9 R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(10):1623\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201370.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"219_CR96","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.semarthrit.2013.04.005","volume":"43","author":"LI Sakkas","year":"2013","unstructured":"Sakkas LI, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013;43(3):325\u201334. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.04.005.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"219_CR97","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.3899\/jrheum.140879","volume":"41","author":"S Rose","year":"2014","unstructured":"Rose S, Toloza S, Bautista-Molano W, Helliwell PS, GRAPPA Dactylitis Study Group. Comprehensive treatment of dactylitis in psoriatic arthritis. J Rheumatol. 2014;41(11):2295\u2013300. https:\/\/doi.org\/10.3899\/jrheum.140879.","journal-title":"J Rheumatol"},{"issue":"4","key":"219_CR98","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1346-8138.1981.tb02551.x","volume":"8","author":"H Katayama","year":"1981","unstructured":"Katayama H, Kawada A. Exacerbation of psoriasis induced by indomethacin. J Dermatol. 1981;8(4):323\u20137. https:\/\/doi.org\/10.1111\/j.1346-8138.1981.tb02551.x.","journal-title":"J Dermatol"},{"issue":"1","key":"219_CR99","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2133.1983.tb04000.x","volume":"109","author":"H Reshad","year":"1983","unstructured":"Reshad H, Hargreaves GK, Vickers CF. Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenbutazone. Br J Dermatol. 1983;109(1):111\u20133. https:\/\/doi.org\/10.1111\/j.1365-2133.1983.tb04000.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"219_CR100","first-page":"45","volume":"38","author":"E Ben-Chetrit","year":"1986","unstructured":"Ben-Chetrit E, Rubinow A. Exacerbation of psoriasis by ibuprofen. Cutis. 1986;38(1):45.","journal-title":"Cutis"},{"issue":"4","key":"219_CR101","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/00015550510032823","volume":"85","author":"AD Cohen","year":"2005","unstructured":"Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol. 2005;85(4):299\u2013303. https:\/\/doi.org\/10.1080\/00015550510032823.","journal-title":"Acta Derm Venereol"},{"key":"219_CR102","unstructured":"Kvien TK, Heiberg, Lie E, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S188-S194."},{"key":"219_CR103","doi-asserted-by":"publisher","unstructured":"Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).\u00a0Ann Rheum Dis. 2014;73(2):407\u2010413. https:\/\/doi.org\/10.1136\/annrheumdis-2012-20197","DOI":"10.1136\/annrheumdis-2012-20197"},{"key":"219_CR104","doi-asserted-by":"publisher","unstructured":"Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis.\u00a0Cochrane Database Syst Rev. 2000;(3):CD000212. https:\/\/doi.org\/10.1002\/14651858.CD000212","DOI":"10.1002\/14651858.CD000212"},{"issue":"4","key":"219_CR105","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.1780270403","volume":"27","author":"RF Willkens","year":"1984","unstructured":"Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27(4):376\u201381. https:\/\/doi.org\/10.1002\/art.1780270403.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"219_CR106","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","volume":"27","author":"R Scarpa","year":"2008","unstructured":"Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27(7):823\u20136. https:\/\/doi.org\/10.1007\/s10067-007-0787-7.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"219_CR107","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368\u201377. https:\/\/doi.org\/10.1093\/rheumatology\/kes001.","journal-title":"Rheumatology (Oxford)"},{"key":"219_CR108","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1471-2474-14-101","volume":"14","author":"LC Coates","year":"2013","unstructured":"Coates LC, Navarro-Coy N, Brown SR, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord. 2013;14:101. https:\/\/doi.org\/10.1186\/1471-2474-14-101.","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"219_CR109","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71(7):1112\u201324. https:\/\/doi.org\/10.1002\/art.40851.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"219_CR110","first-page":"2274","volume":"28","author":"C Salvarani","year":"2001","unstructured":"Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001;28(10):2274\u201382.","journal-title":"J Rheumatol"},{"issue":"5","key":"219_CR111","first-page":"589","volume":"13","author":"A Spadaro","year":"1995","unstructured":"Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995;13(5):589\u201393.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"219_CR112","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3899\/jrheum.110242","volume":"38","author":"GN Karanikolas","year":"2011","unstructured":"Karanikolas GN, Koukli EM, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol. 2011;38(11):2466\u201374. https:\/\/doi.org\/10.3899\/jrheum.110242.","journal-title":"J Rheumatol"},{"issue":"6","key":"219_CR113","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"JP Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50(6):1939\u201350. https:\/\/doi.org\/10.1002\/art.20253.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"219_CR114","first-page":"728","volume":"32","author":"A Asiri","year":"2014","unstructured":"Asiri A, Thavaneswaran A, Kalman-Lamb G, Chandran V, Gladman DD. The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol. 2014;32(5):728\u201331.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"219_CR115","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/rheumatology\/35.7.664","volume":"35","author":"B Combe","year":"1996","unstructured":"Combe B, Goupille P, Kuntz JL, Tebib J, Liot\u00e9 F, Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol. 1996;35(7):664\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/35.7.664.","journal-title":"Br J Rheumatol"},{"issue":"10","key":"219_CR116","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/rheumatology\/32.10.923","volume":"32","author":"SM Fraser","year":"1993","unstructured":"Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol. 1993;32(10):923\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/32.10.923.","journal-title":"Br J Rheumatol"},{"issue":"5","key":"219_CR117","first-page":"894","volume":"22","author":"AK Gupta","year":"1995","unstructured":"Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. 1995;22(5):894\u20138.","journal-title":"J Rheumatol"},{"key":"219_CR118","doi-asserted-by":"publisher","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial [published correction appears in Lancet. 2020 Apr 4;395(10230):1114]. Lancet. 2020;395(10230):1115\u20131125. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"219_CR119","doi-asserted-by":"publisher","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial [published correction appears in Lancet. 2020 Apr 4;395(10230):1114].\u00a0Lancet. 2020;395(10230):1126\u20131136. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4.","DOI":"10.1016\/S0140-6736(20)30263-4"},{"issue":"1","key":"219_CR120","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215386.","journal-title":"Ann Rheum Dis"},{"key":"219_CR121","doi-asserted-by":"publisher","unstructured":"McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet. 2020;395(10235):1496\u20131505. https:\/\/doi.org\/10.1016\/S0140-6736(20)30564-X","DOI":"10.1016\/S0140-6736(20)30564-X"},{"issue":"4","key":"219_CR122","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"P Mease","year":"2011","unstructured":"Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939\u201348. https:\/\/doi.org\/10.1002\/art.30176.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"219_CR123","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279\u201389. https:\/\/doi.org\/10.1002\/art.21306.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"219_CR124","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203696.","journal-title":"Ann Rheum Dis"},{"issue":"9227","key":"219_CR125","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(00)02530-7.","journal-title":"Lancet"},{"issue":"7","key":"219_CR126","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264\u201372. https:\/\/doi.org\/10.1002\/art.20335.","journal-title":"Arthritis Rheum"},{"key":"219_CR127","doi-asserted-by":"publisher","unstructured":"Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study [published correction appears in Arthritis Rheum. 2010 Aug;62(8):2555]. Arthritis Rheum. 2009;60(4):976\u2013986. https:\/\/doi.org\/10.1002\/art.24403","DOI":"10.1002\/art.24403"},{"key":"219_CR128","doi-asserted-by":"publisher","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) [published correction appears in Arthritis Rheum. 2005 Sep;52(9):2951]. Arthritis Rheum. 2005;52(4):1227\u20131236. https:\/\/doi.org\/10.1002\/art.20967","DOI":"10.1002\/art.20967"},{"issue":"1","key":"219_CR129","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709.","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"219_CR130","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1412679.","journal-title":"N Engl J Med"},{"issue":"9999","key":"219_CR131","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(15)61134-5.","journal-title":"Lancet"},{"key":"219_CR132","doi-asserted-by":"publisher","unstructured":"Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial [published correction appears in Lancet. 2009 Apr 18;373(9672):1340] [published correction appears in Lancet. 2010 Nov 6;376(9752):1542]. Lancet. 2009;373(9664):633\u2013640. https:\/\/doi.org\/10.1016\/S0140-6736(09)60140-9","DOI":"10.1016\/S0140-6736(09)60140-9"},{"issue":"16","key":"219_CR133","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1615975.","journal-title":"N Engl J Med"},{"key":"219_CR134","doi-asserted-by":"publisher","unstructured":"Wilsdon TD, Whittle SL, Thynne TR, Mangoni AA. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019;1(1):CD012722. https:\/\/doi.org\/10.1002\/14651858.CD012722.pub2","DOI":"10.1002\/14651858.CD012722.pub2"},{"key":"219_CR135","doi-asserted-by":"crossref","unstructured":"Baraliakos X, Coates L, Gossec L, Jeka S, Mera A, Schulz B, Rissler M, Das Gupta A, Perella C, Pournara E. Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/secukinumab-improves-axial-manifestations-in-patients-with-psoriatic-arthritis-and-inadequate-response-to-nsaids-primary-analysis-of-phase-3-trial\/. Accessed 11 Aug 2021","DOI":"10.1136\/annrheumdis-2019-eular.2932"},{"issue":"9","key":"219_CR136","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210724.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"219_CR137","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56(2):476\u201388. https:\/\/doi.org\/10.1002\/art.22379.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"219_CR138","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68(5):702\u20139. https:\/\/doi.org\/10.1136\/ard.2008.092767.","journal-title":"Ann Rheum Dis"},{"key":"219_CR139","unstructured":"Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy [published correction appears in J Rheumatol. 2007 Jun;34(6):1439]. J Rheumatol. 2007;34(5):1040\u20131050. Erratum in: J Rheumatol. 2007;34(6):1439."},{"issue":"4","key":"219_CR140","first-page":"712","volume":"33","author":"PJ Mease","year":"2006","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33(4):712\u201321.","journal-title":"J Rheumatol"},{"issue":"6","key":"219_CR141","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3899\/jrheum.091093","volume":"37","author":"PJ Mease","year":"2010","unstructured":"Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol. 2010;37(6):1221\u20137. https:\/\/doi.org\/10.3899\/jrheum.091093.","journal-title":"J Rheumatol"},{"issue":"10","key":"219_CR142","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/acr.22044","volume":"65","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, McInnes IB, Krueger GG, et al. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013;65(10):1666\u201373. https:\/\/doi.org\/10.1002\/acr.22044.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"219_CR143","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1136\/annrheumdis-2012-202035","volume":"72","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013;72(11):1777\u201385. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202035.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"219_CR144","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689\u201394. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204902.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"219_CR145","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol. 2017;69(11):2151\u201361. https:\/\/doi.org\/10.1002\/art.40226.","journal-title":"Arthritis Rheumatol"},{"issue":"10136","key":"219_CR146","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","volume":"391","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)30952-8.","journal-title":"Lancet"},{"issue":"4","key":"219_CR147","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/ard.2006.058339","volume":"66","author":"A Kavanaugh","year":"2007","unstructured":"Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66(4):498\u2013505. https:\/\/doi.org\/10.1136\/ard.2006.058339.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"219_CR148","first-page":"869","volume":"35","author":"CE Antoni","year":"2008","unstructured":"Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35(5):869\u201376.","journal-title":"J Rheumatol"},{"issue":"9","key":"219_CR149","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3899\/jrheum.160275","volume":"43","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, McInnes IB, Mease PJ, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol. 2016;43(9):1713\u20137. https:\/\/doi.org\/10.3899\/jrheum.160275.","journal-title":"J Rheumatol"},{"issue":"6","key":"219_CR150","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204655.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"219_CR151","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2019.06.001","volume":"49","author":"C Lu","year":"2019","unstructured":"Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis. Semin Arthritis Rheum. 2019;49(3):381\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"219_CR152","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41927-018-0011-1","volume":"12","author":"V Strand","year":"2018","unstructured":"Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A. Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis. BMC Rheumatol. 2018;12(2):3. https:\/\/doi.org\/10.1186\/s41927-018-0011-1.","journal-title":"BMC Rheumatol"},{"issue":"3","key":"219_CR153","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, McCaskill RM, Zueger P, Pangan AL, Tillett W. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020;80(3):312\u201320. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218870.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"219_CR154","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","volume":"20","author":"SB Desai","year":"2006","unstructured":"Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20(4):757\u201390. https:\/\/doi.org\/10.1016\/j.berh.2006.06.002.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"219_CR155","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756\u2013761. https:\/\/doi.org\/10.1002\/art.22768","DOI":"10.1002\/art.22768"},{"issue":"2","key":"219_CR156","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2174\/138945010790310009","volume":"11","author":"EL Culver","year":"2010","unstructured":"Culver EL, Travis SP. How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Curr Drug Targets. 2010;11(2):198\u2013218. https:\/\/doi.org\/10.2174\/138945010790310009.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"219_CR157","doi-asserted-by":"publisher","first-page":"e000044","DOI":"10.1136\/rmdopen-2014-000044","volume":"1","author":"X Mariette","year":"2015","unstructured":"Mariette X, Vencovsky J, Lortholary O, et al. The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. RMD Open. 2015;1(1):e000044. https:\/\/doi.org\/10.1136\/rmdopen-2014-000044.","journal-title":"RMD Open"},{"issue":"12","key":"219_CR158","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3899\/jrheum.160420","volume":"43","author":"J Kay","year":"2016","unstructured":"Kay J, Fleischmann R, Keystone E, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2016;43(12):2120\u201330. https:\/\/doi.org\/10.3899\/jrheum.160420.","journal-title":"J Rheumatol"},{"issue":"5","key":"219_CR159","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","volume":"167","author":"TF Tsai","year":"2012","unstructured":"Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145\u201352. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11142.x.","journal-title":"Br J Dermatol"},{"issue":"9","key":"219_CR160","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/ard.2009.111500","volume":"69","author":"S Bernatsky","year":"2010","unstructured":"Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010;69(9):1691\u20133. https:\/\/doi.org\/10.1136\/ard.2009.111500.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"219_CR161","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000447086","volume":"7","author":"C Bru\u00e8","year":"2016","unstructured":"Bru\u00e8 C, Mariotti C, Rossiello I, Saitta A, Giovannini A. Demyelinizing neurological disease after treatment with tumor necrosis factor-\u03b1 antagonists. Case Rep Ophthalmol. 2016;7(2):345\u201353. https:\/\/doi.org\/10.1159\/000447086.","journal-title":"Case Rep Ophthalmol"},{"issue":"11","key":"219_CR162","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s00296-011-2216-0","volume":"32","author":"YS Ryu","year":"2012","unstructured":"Ryu YS, Park SH, Kim JM, et al. A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature. Rheumatol Int. 2012;32(11):3481\u20135. https:\/\/doi.org\/10.1007\/s00296-011-2216-0.","journal-title":"Rheumatol Int"},{"issue":"4","key":"219_CR163","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10165-008-0062-z","volume":"18","author":"T Kameda","year":"2008","unstructured":"Kameda T, Dobashi H, Kittaka K, et al. A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod Rheumatol. 2008;18(4):399\u2013402. https:\/\/doi.org\/10.1007\/s10165-008-0062-z.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"219_CR164","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s10067-005-0097-x","volume":"25","author":"M Tanno","year":"2006","unstructured":"Tanno M, Nakamura I, Kobayashi S, Kurihara K, Ito K. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol. 2006;25(6):929\u201333. https:\/\/doi.org\/10.1007\/s10067-005-0097-x.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"219_CR165","first-page":"1202","volume":"33","author":"N Al Saieg","year":"2006","unstructured":"Al Saieg N, Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 2006;33(6):1202\u20134.","journal-title":"J Rheumatol"},{"issue":"5","key":"219_CR166","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/03009740802136164","volume":"37","author":"CF Pfueller","year":"2008","unstructured":"Pfueller CF, Seipelt E, Zipp F, Paul F. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol. 2008;37(5):397\u20139. https:\/\/doi.org\/10.1080\/03009740802136164.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"219_CR167","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/03009740510017887","volume":"34","author":"S Kunzmann","year":"2005","unstructured":"Kunzmann S, Warmuth-Metz M, Girschick HJ. Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still\u2019s disease. Scand J Rheumatol. 2005;34(1):76\u20138. https:\/\/doi.org\/10.1080\/03009740510017887.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"219_CR168","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","volume":"49","author":"T Ding","year":"2010","unstructured":"Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford). 2010;49(11):2217\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keq249a.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"219_CR169","first-page":"991","volume":"35","author":"A Marchesoni","year":"2017","unstructured":"Marchesoni A, Olivieri I, Salvarani C, et al. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol. 2017;35(6):991\u20131010.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"219_CR170","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","volume":"7","author":"BM Segal","year":"2008","unstructured":"Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7(9):796\u2013804. https:\/\/doi.org\/10.1016\/S1474-4422(08)70173-X.","journal-title":"Lancet Neurol"},{"issue":"7","key":"219_CR171","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","volume":"263","author":"E Havrdov\u00e1","year":"2016","unstructured":"Havrdov\u00e1 E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263(7):1287\u201395. https:\/\/doi.org\/10.1007\/s00415-016-8128-x.","journal-title":"J Neurol"},{"issue":"16","key":"219_CR172","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377(16):1525\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1615977.","journal-title":"N Engl J Med"},{"key":"219_CR173","doi-asserted-by":"publisher","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","volume":"6","author":"A Ruyssen-Witrand","year":"2020","unstructured":"Ruyssen-Witrand A, Perry R, Watkins C, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020;6:e001117. https:\/\/doi.org\/10.1136\/rmdopen-2019-001117.","journal-title":"RMD Open"},{"issue":"1","key":"219_CR174","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/RHU.0000000000000583","volume":"24","author":"J Bilal","year":"2018","unstructured":"Bilal J, Riaz IB, Kamal MU, Elyan M, Sudano D, Khan MA. A systematic review and meta-analysis of efficacy and safety of novel interleukin inhibitors in the management of psoriatic arthritis. J Clin Rheumatol. 2018;24(1):6\u201313. https:\/\/doi.org\/10.1097\/RHU.0000000000000583.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"219_CR175","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/rheumatology\/kex452","volume":"57","author":"D Wu","year":"2018","unstructured":"Wu D, Yue J, Tam LS. Efficacy and safety of biologics targeting interleukin-6, -12\/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford). 2018;57(3):563\u201371. https:\/\/doi.org\/10.1093\/rheumatology\/kex452.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"219_CR176","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150\u20137. https:\/\/doi.org\/10.1136\/ard.2004.032268.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"219_CR177","doi-asserted-by":"publisher","first-page":"e000606","DOI":"10.1136\/rmdopen-2017-000606","volume":"4","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Gladman DD, Samad AS, et al. Design and rationale of the study of etanercept and methotrexate in combination or as monotherapy in subjects with psoriatic arthritis (SEAM-PsA). RMD Open. 2018;4(1):e000606. https:\/\/doi.org\/10.1136\/rmdopen-2017-000606.","journal-title":"RMD Open"},{"issue":"3","key":"219_CR178","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ard.2007.073544","volume":"67","author":"LE Kristensen","year":"2008","unstructured":"Kristensen LE, G\u00fclfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008;67(3):364\u20139. https:\/\/doi.org\/10.1136\/ard.2007.073544.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"219_CR179","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli KM, Lie E, van der Heijde D, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2014;73(1):132\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202347.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"219_CR180","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"B Glintborg","year":"2011","unstructured":"Glintborg B, \u00d8stergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382\u201390. https:\/\/doi.org\/10.1002\/art.30117.","journal-title":"Arthritis Rheum"},{"key":"219_CR181","doi-asserted-by":"publisher","unstructured":"Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register [published correction appears in Rheumatology (Oxford). 2017 Apr 1;56(4):672\u2013673]. Rheumatology (Oxford). 2010;49(4):697\u2013705. https:\/\/doi.org\/10.1093\/rheumatology\/kep423","DOI":"10.1093\/rheumatology\/kep423"},{"issue":"1","key":"219_CR182","doi-asserted-by":"publisher","first-page":"e000181","DOI":"10.1136\/rmdopen-2015-000181","volume":"1","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;1(1):e000181. https:\/\/doi.org\/10.1136\/rmdopen-2015-000181.","journal-title":"RMD Open"},{"issue":"10086","key":"219_CR183","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(17)31429-0.","journal-title":"Lancet"},{"issue":"9894","key":"219_CR184","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2.","journal-title":"Lancet"},{"issue":"5","key":"219_CR185","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/ard.2007.082925","volume":"67","author":"LC Coates","year":"2008","unstructured":"Coates LC, Cawkwell LS, Ng NW, et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis. 2008;67(5):717\u20139. https:\/\/doi.org\/10.1136\/ard.2007.082925.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"219_CR186","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","volume":"72","author":"KM Fagerli","year":"2013","unstructured":"Fagerli KM, Lie E, van der Heijde D, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013;72(11):1840\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203018.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"219_CR187","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00296-019-04416-3","volume":"40","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Becciolini A, Carletto A, et al. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. Rheumatol Int. 2020;40(2):263\u201372. https:\/\/doi.org\/10.1007\/s00296-019-04416-3.","journal-title":"Rheumatol Int"},{"issue":"1","key":"219_CR188","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3899\/jrheum.150744","volume":"43","author":"LE Kristensen","year":"2016","unstructured":"Kristensen LE, Lie E, Jacobsson LT, et al. Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from Southern Sweden. J Rheumatol. 2016;43(1):81\u20137. https:\/\/doi.org\/10.3899\/jrheum.150744.","journal-title":"J Rheumatol"},{"issue":"1","key":"219_CR189","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","volume":"50","author":"JF Simard","year":"2011","unstructured":"Simard JF, Arkema EV, Sundstr\u00f6m A, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011;50(1):204\u201313. https:\/\/doi.org\/10.1093\/rheumatology\/keq326.","journal-title":"Rheumatology (Oxford)"},{"issue":"9\u201310","key":"219_CR190","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","volume":"160","author":"G Haberhauer","year":"2010","unstructured":"Haberhauer G, Strehblow C, Fasching P. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr. 2010;160(9\u201310):220\u20134. https:\/\/doi.org\/10.1007\/s10354-010-0795-0.","journal-title":"Wien Med Wochenschr"},{"issue":"1","key":"219_CR191","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jbspin.2014.08.001","volume":"82","author":"AS Soubrier","year":"2015","unstructured":"Soubrier AS, Bele-Philippe P, Cortet B, et al. Treatment response, drug survival and safety of anti-tumour necrosis factor \u03b1 therapy in 193 patients with psoriatic arthritis: a twelve-year \u201creal life\u201d experience. Joint Bone Spine. 2015;82(1):31\u20137. https:\/\/doi.org\/10.1016\/j.jbspin.2014.08.001.","journal-title":"Joint Bone Spine"},{"key":"219_CR192","doi-asserted-by":"publisher","unstructured":"Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8(1):R29. https:\/\/doi.org\/10.1186\/ar1881","DOI":"10.1186\/ar1881"},{"issue":"2","key":"219_CR193","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11(2):R52. https:\/\/doi.org\/10.1186\/ar2670.","journal-title":"Arthritis Res Ther"},{"key":"219_CR194","doi-asserted-by":"crossref","unstructured":"Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88\u201397","DOI":"10.1016\/j.jaad.2017.01.037"},{"issue":"9","key":"219_CR195","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s10067-017-3916-y","volume":"37","author":"A Soare","year":"2018","unstructured":"Soare A, Gheorghiu AM, Aram\u0103 V, Bumb\u0103cea D, Dobrot\u0103 R, Onea\u0163\u0103 R, Pintilie S, Milicescu M, Ancu\u0163a I, Martin A, Sasu M, Ciofu C, Macovei L, Stoica V, Bojinc\u0103 M, Mihai C. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol. Clin Rheumatol. 2018;37(9):2391\u20137. https:\/\/doi.org\/10.1007\/s10067-017-3916-y.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"219_CR196","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/rheumatology\/key241","volume":"58","author":"KM Fagerli","year":"2019","unstructured":"Fagerli KM, Kearsley-Fleet L, Mercer LK, Watson K, Packham J, Symmons DPM, Hyrich KL. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2019;58(1):80\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/key241.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"219_CR197","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2018-213463","volume":"77","author":"B Michelsen","year":"2018","unstructured":"Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML. Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis. 2018;77(12):1736\u201341. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213463.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"219_CR198","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353. https:\/\/doi.org\/10.1136\/ard.2008.102053.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"219_CR199","first-page":"78","volume":"7","author":"C Popescu","year":"2014","unstructured":"Popescu C, Trandafir M, Badica A, Morar F, Predeteanu D. Ankylosing spondylitis functional and activity indices in clinical practice. J Med Life. 2014;7(1):78\u201383.","journal-title":"J Med Life"},{"issue":"Suppl 11","key":"219_CR200","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S47-58. https:\/\/doi.org\/10.1002\/acr.20575.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"219_CR201","doi-asserted-by":"publisher","unstructured":"Machado PM, Landew\u00e9 R, Heijde DV. Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539\u20131540. doi: https:\/\/doi.org\/10.1136\/annrheumdis-2018-213184","DOI":"10.1136\/annrheumdis-2018-213184"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-021-00219-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T01:51:10Z","timestamp":1699840270000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-021-00219-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":201,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1186\/s42358-021-00219-y","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"2 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}],"article-number":"69"}}